#GDF15
Lucie Zerarga, et al.: A corticopapillary Gdf15 response links maladaptive collecting duct remodeling to polyuria during lithium exposure https://hal.science/hal-05855294v1 [sdv]
November 18, 2026 at 3:01 AM
Billiet, Morla, Vidal-Petiot, Wirth, Laney, Baron, Amar, Cheval, Crambert: Renal adaptation to primary aldosteronism requires GDF15 to control plasma potassium level in mice and human https://hal.science/hal-05855279v1 [sdv]
November 18, 2026 at 3:01 AM
Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.11.14.26368038v1
November 17, 2026 at 8:02 PM
Ahora en directo: «Gluconeogénesis, fibrosis hepática y GDF15», conferencia del Prof. Manuel Vázquez-Carrera (Universidad de Barcelona) en la RANFE. www.youtube.com/watch?v=O9Uq...
Gluconeogénesis, fibrosis hepática y GDF15, con Manuel Vázquez-Carrera | RANFE
YouTube video by Real Academia Nacional de Farmacia RANF
www.youtube.com
November 12, 2026 at 6:12 PM
Ya disponible la conferencia «Gluconeogénesis, fibrosis hepática y GDF15», en la que el Prof. Manuel Vázquez-Carrera explicó el papel protector de la proteína GDF15 frente a la diabetes tipo 2.

Crónica: ranf.com/noticia/gluc...
Sesión: ranf.com/sesion/gluco...
November 13, 2026 at 10:59 AM
Hoy jueves 12 de noviembre, a las 19:00, Manuel Vázquez-Carrera (Universidad de Barcelona) imparte en la RANFE la conferencia «Gluconeogénesis, fibrosis hepática y GDF15». Presencial y en directo en ranf.tv. ranf.com/sesion/gluco...
November 12, 2026 at 11:09 AM
Online now: Macronutrient composition and genetic background determine the response to a ketogenic diet in mice
Macronutrient composition and genetic background determine the response to a ketogenic diet in mice
Zhang et al. show that dietary protein and genetic background shape ketogenic diet response. Unlike other strains, C57BL/6J mice eat less and lose weight on a low-protein KD. NNT and NLRP12 mutations, in combination with the diet, activate a stress and inflammation response to induce GDF15 and LCN2, which reduce food intake and decrease weight.
dlvr.it
November 18, 2026 at 4:42 PM
Take a little time out of your day to check out this Short Report, Secreted GDF15 maintains transcriptional responses during #DNA damage-mediated senescence in human beta cells (Nayara Rampazzo Morelli et al. @UM_physiology):

https://ow.ly/jsGU5104gQl
November 5, 2026 at 8:00 PM
Muscle-derived GDF15 exerts both local muscle-autonomous and systemic protective effects, uncovering a previously unrecognized muscle-to-organ cross-talk axis.

Read here ➡️ doi.org/10.2337/db26-0082
November 5, 2026 at 10:15 PM
GDF15 modifies NAD+ salvage pathway and dampens immune response in mitochondrial disease

www.biorxiv.org/content/10.6...
GDF15 modifies NAD+ salvage pathway and dampens immune response in mitochondrial disease
Mitochondrial integrated stress response (ISRmt) is a main mammalian metabolic stress pathway, with local ISRmt and a systemic response via circulating metabokines GDF15 and FGF21 as early signs of th...
www.biorxiv.org
November 3, 2026 at 10:17 AM
GDF15 modifies NAD+ salvage pathway and dampens immune response in mitochondrial disease https://www.biorxiv.org/content/10.64898/2026.10.31.763316v1
November 3, 2026 at 7:30 AM
GDF15 modifies NAD+ salvage pathway and dampens immune response in mitochondrial disease https://www.biorxiv.org/content/10.64898/2026.10.31.763316v1
November 3, 2026 at 7:30 AM
いまの空いてる時間を活用して英検準一でも取ったろかと思って、とりあえず過去問見てどんなレベルか確認しようとしたんだけど、頭使うと気持ち悪さ倍増するからやっぱ無理かも😓
眼精疲労もあるから、唯一読む活字が推理小説なのにそれも無理
もうアレコレ足掻くのやめてボーっとアホなことだけ考えて過ごすしかなさそう〜…
でもそろそろ落ち着いてくれませんかね😭GDF15への耐性が低いっぽい
November 4, 2026 at 4:17 AM
Why do some women experience such severe pregnancy sickness?

In our new blog, Neave Smith explores the role of GDF15, a placental hormone that acts on the brain, and how sensitivity to this hormone may contribute to hyperemesis gravidarum.
October 29, 2026 at 9:03 PM
We actually know, as of a couple years ago! There’s a hormone produced by foetuses in pregnancy (GDF15). Some parents have a more sensitive response to it, some foetuses produce more. When you get both, HG. That’s why someone who has HG with one sperm donor may not have it with another. Genetics.
October 28, 2026 at 6:28 PM
Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis @PLOSBiology.org
Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis
by Xiao Peng Liu, Xiao Zhang, Chun Xia Cai, Miao Miao Qin, Xiang Kai Leng, Jia Hao Chen, Yi Fan Han, Jun Ying Xiao, Jia He Huang, Jiang Wei Wu Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality, yet its underlying mechanism remains elusive. Here, we show that growth differentiation factor 15 (GDF15) levels are significantly reduced in the placenta and fetal circulation in mouse and pig FGR models and correlate positively with fetal weight. Placenta-specific GDF15 deficiency causes FGR, while placenta-specific Gdf15 mRNA delivery through targeted lipid nanoparticle (LNP) effectively alleviates FGR. Mechanistically, placental GDF15 is a major contributor to the fetal circulating GDF15 pool and enters the fetal compartment, where it activates the hepatic STAT3 signaling pathway to stimulate IGF2 production during pregnancy. Placental GDF15 deficiency decreases hepatic STAT3 phosphorylation and IGF2 levels in fetuses. Inhibition of STAT3 in primary mouse fetal hepatocytes blocks GDF15-induced IGF2 upregulation. Placenta-specific Gdf15 mRNA-LNP administration rescues the decreased hepatic p-STAT3 and IGF2 levels in FGR fetuses. Collectively, our findings identify a placenta-fetal liver metabolic axis where placental GDF15 promotes fetal growth by activating the fetal hepatic STAT3-IGF2 pathway, revealing a potential therapeutic target for FGR.
dlvr.it
October 26, 2026 at 6:42 AM
Circulating levels of GDF15 change during pregnancy, and low levels have been linked to fetal growth restriction in clinical studies. This study shows that placenta-specific GDF15 is required to support fetal growth in mice.
🧪 #AcademicSky #placenta #development
plos.io/3U4gLzh
October 23, 2026 at 4:03 PM
At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing antibody visugromab + nivolumab produced encouraging pathological complete response with no new safety signals.
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial - Nature Medicine
As presented at the ESMO Congress 2026: In this exploratory, nonrandomized phase 2a trial, treatment of patients with immune checkpoint inhibitor-naive muscle-invasive bladder cancer with the GDF-15-neutralizing antibody visugromab and nivolumab produced encouraging pathological complete response and radiographic response rates with no new safety signals, supporting further evaluation in larger randomized studies.
dlvr.it
October 24, 2026 at 9:18 PM
Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis @PLOSBiology.org
Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis
by Xiao Peng Liu, Xiao Zhang, Chun Xia Cai, Miao Miao Qin, Xiang Kai Leng, Jia Hao Chen, Yi Fan Han, Jun Ying Xiao, Jia He Huang, Jiang Wei Wu Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality, yet its underlying mechanism remains elusive. Here, we show that growth differentiation factor 15 (GDF15) levels are significantly reduced in the placenta and fetal circulation in mouse and pig FGR models and correlate positively with fetal weight. Placenta-specific GDF15 deficiency causes FGR, while placenta-specific Gdf15 mRNA delivery through targeted lipid nanoparticle (LNP) effectively alleviates FGR. Mechanistically, placental GDF15 is a major contributor to the fetal circulating GDF15 pool and enters the fetal compartment, where it activates the hepatic STAT3 signaling pathway to stimulate IGF2 production during pregnancy. Placental GDF15 deficiency decreases hepatic STAT3 phosphorylation and IGF2 levels in fetuses. Inhibition of STAT3 in primary mouse fetal hepatocytes blocks GDF15-induced IGF2 upregulation. Placenta-specific Gdf15 mRNA-LNP administration rescues the decreased hepatic p-STAT3 and IGF2 levels in FGR fetuses. Collectively, our findings identify a placenta-fetal liver metabolic axis where placental GDF15 promotes fetal growth by activating the fetal hepatic STAT3-IGF2 pathway, revealing a potential therapeutic target for FGR.
dlvr.it
October 24, 2026 at 12:42 AM
Renal adaptation to primary aldosteronism requires GDF15 to control plasma potassium level in mice and human. https://www.biorxiv.org/content/10.64898/2026.10.18.759915v1
October 23, 2026 at 4:00 AM
Renal adaptation to primary aldosteronism requires GDF15 to control plasma potassium level in mice and human. https://www.biorxiv.org/content/10.64898/2026.10.18.759915v1
October 23, 2026 at 4:00 AM
Circulating levels of GDF15 change during pregnancy, and low levels have been linked to fetal growth restriction in clinical studies. This study shows that placenta-specific GDF15 is required to support fetal growth in mice.
🧪 #AcademicSky #placenta #development
plos.io/3U4gLzh
October 22, 2026 at 12:02 PM
Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis @PLOSBiology.org
Deficiency of placental GDF15 causes fetal growth restriction by inhibiting fetal hepatic STAT3-IGF2 axis
by Xiao Peng Liu, Xiao Zhang, Chun Xia Cai, Miao Miao Qin, Xiang Kai Leng, Jia Hao Chen, Yi Fan Han, Jun Ying Xiao, Jia He Huang, Jiang Wei Wu Fetal growth restriction (FGR) is a major cause of perinatal morbidity and mortality, yet its underlying mechanism remains elusive. Here, we show that growth differentiation factor 15 (GDF15) levels are significantly reduced in the placenta and fetal circulation in mouse and pig FGR models and correlate positively with fetal weight. Placenta-specific GDF15 deficiency causes FGR, while placenta-specific Gdf15 mRNA delivery through targeted lipid nanoparticle (LNP) effectively alleviates FGR. Mechanistically, placental GDF15 is a major contributor to the fetal circulating GDF15 pool and enters the fetal compartment, where it activates the hepatic STAT3 signaling pathway to stimulate IGF2 production during pregnancy. Placental GDF15 deficiency decreases hepatic STAT3 phosphorylation and IGF2 levels in fetuses. Inhibition of STAT3 in primary mouse fetal hepatocytes blocks GDF15-induced IGF2 upregulation. Placenta-specific Gdf15 mRNA-LNP administration rescues the decreased hepatic p-STAT3 and IGF2 levels in FGR fetuses. Collectively, our findings identify a placenta-fetal liver metabolic axis where placental GDF15 promotes fetal growth by activating the fetal hepatic STAT3-IGF2 pathway, revealing a potential therapeutic target for FGR.
dlvr.it
October 22, 2026 at 4:40 PM